Robbert G M Bredius

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1509737/publications.pdf

Version: 2024-02-01

53751 58549 7,386 129 45 citations h-index papers

g-index 131 131 131 7503 docs citations times ranked citing authors all docs

82

#	Article	IF	CITATIONS
1	Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet, The, 2003, 361, 553-560.	6.3	524
2	Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better?. Journal of Allergy and Clinical Immunology, 2010, 126, 602-610.e11.	1.5	385
3	Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nature Genetics, 2007, 39, 960-962.	9.4	346
4	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet, The, 2014, 383, 436-448.	6.3	322
5	DOCK8 Deficiency: Clinical and Immunological Phenotype and Treatment Options - a Review of 136 Patients. Journal of Clinical Immunology, 2015, 35, 189-198.	2.0	284
6	Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematology,the, 2015, 2, e194-e203.	2.2	228
7	Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood, 2008, 111, 439-445.	0.6	216
8	Fca Receptor lia (Cd32) Polymorphism In Fulminant Meningococcal Septic. Journal of Infectious Diseases, 1994, 170, 848-853.	1.9	205
9	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematology,the, 2016, 3, e526-e536.	2.2	197
10	Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. Lancet Haematology,the, 2017, 4, e183-e191.	2.2	154
11	Outcome of hematopoietic stem cell transplantation for adenosine deaminase–deficient severe combined immunodeficiency. Blood, 2012, 120, 3615-3624.	0.6	151
12	Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood, 2017, 130, 2682-2688.	0.6	140
13	The Same ll̂ºBα Mutation in Two Related Individuals Leads to Completely Different Clinical Syndromes. Journal of Experimental Medicine, 2004, 200, 559-568.	4.2	135
14	Effect of Ribavirin on the Plasma Viral DNA Load in Patients with Disseminating Adenovirus Infection. Clinical Infectious Diseases, 2004, 38, 1521-1525.	2.9	124
15	Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood, 2003, 103, 1152-1157.	0.6	116
16	Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology, 2016, 55, 902-910.	0.9	116
17	Prospective study of renal insufficiency after bone marrow transplantation. Pediatric Nephrology, 2002, 17, 1032-1037.	0.9	115
18	Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients. Clinical Pharmacokinetics, 2012, 51, 331-345.	1.6	115

#	Article	IF	CITATIONS
19	Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 231-241.	2.0	107
20	Complete Suppression of the Gut Microbiome Prevents Acute Graft-Versus-Host Disease following Allogeneic Bone Marrow Transplantation. PLoS ONE, 2014, 9, e105706.	1.1	89
21	How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more!. Bone Marrow Transplantation, 2005, 35, 645-652.	1.3	83
22	Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab. Biology of Blood and Marrow Transplantation, 2015, 21, 473-482.	2.0	80
23	Primary immunodeficiencies in the Netherlands: National patient data demonstrate the increased risk of malignancy. Clinical Immunology, 2015, 156, 154-162.	1.4	80
24	Glutathione S-transferase Polymorphisms Are Not Associated With Population Pharmacokinetic Parameters of Busulfan in Pediatric Patients. Therapeutic Drug Monitoring, 2008, 30, 504-510.	1.0	79
25	Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing. Clinical Pharmacokinetics, 2015, 54, 435-446.	1.6	79
26	Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia, 2011, 25, 1471-1483.	3.3	78
27	A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clinical and Experimental Immunology, 2014, 176, 394-400.	1.1	75
28	The role of Fcl^3 receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clinical and Experimental Immunology, 2000, 120, 338-345.	1.1	73
29	Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome. Molecular Therapy, 2013, 21, 175-184.	3.7	72
30	Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation. British Journal of Haematology, 2005, 131, 231-236.	1.2	70
31	Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplantation, 2005, 35, 17-23.	1.3	69
32	Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 88-98.	2.0	69
33	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1608-1614.	2.0	69
34	Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 848-855.	2.0	67
35	Management of Epstein-Barr Virus (EBV) Reactivation after Allogeneic Stem Cell Transplantation by Simultaneous Analysis of EBV DNA Load and EBV-Specific T Cell Reconstitution. Clinical Infectious Diseases, 2006, 42, 1743-1748.	2.9	65
36	Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1970-1985.e4.	2.0	64

#	Article	IF	CITATIONS
37	Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. Journal of Allergy and Clinical Immunology, 2019, 143, 2238-2253.	1.5	60
38	Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discovery Today, 2014, 19, 1572-1586.	3.2	58
39	Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Biology of Blood and Marrow Transplantation, 2018, 24, 772-778.	2.0	58
40	Prospective Study of Respiratory Viral Infections in Pediatric Hemopoietic Stem Cell Transplantation Patients. Pediatric Infectious Disease Journal, 2004, 23, 518-522.	1.1	53
41	The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. Journal of Experimental Medicine, 2009, 206, 735-742.	4.2	53
42	Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opinion on Therapeutic Targets, 2011, 15, 1003-1021.	1.5	51
43	Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation. Blood, 2010, 116, 27-35.	0.6	50
44	Early Cytomegalovirus Reactivation Leaves a Specific and Dynamic Imprint on the Reconstituting T Cell Compartment Long-Term after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 655-661.	2.0	50
45	Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. British Journal of Clinical Pharmacology, 2002, 53, 386-389.	1.1	49
46	Wiskott-Aldrich syndrome protein–mediated actin dynamics control type-l interferon production in plasmacytoid dendritic cells. Journal of Experimental Medicine, 2013, 210, 355-374.	4.2	49
47	Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Archives of Disease in Childhood, 2014, 99, 267-272.	1.0	46
48	Long-term renal function after hemopoietic stem cell transplantation in children. Bone Marrow Transplantation, 2005, 36, 605-610.	1.3	45
49	Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. British Journal of Haematology, 2005, 128, 571-577.	1.2	44
50	Persistence and Antiviral Resistance of Varicella Zoster Virus in Hematological Patients. Clinical Infectious Diseases, 2013, 56, 335-343.	2.9	44
51	Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplantation, 2005, 36, 99-105.	1.3	43
52	Immunological profile of Fanconi anemia: A multicentric retrospective analysis of 61 patients. American Journal of Hematology, 2013, 88, 472-476.	2.0	43
53	Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. Journal of Clinical Immunology, 2021, 41, 1633-1647.	2.0	43
54	Genotypic and Phenotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses Isolated from Haematopoietic Stem Cell Transplant Recipients. Antiviral Therapy, 2004, 9, 565-575.	0.6	42

#	Article	IF	CITATIONS
55	An evaluation of the TREC assay with regard to the integration of SCID screening into the Dutch newborn screening program. Clinical Immunology, 2017, 180, 106-110.	1.4	41
56	Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2019, 10, 315.	2.2	41
57	Hematopoietic Stem Cell Transplantation Corrects the Immunologic Abnormalities Associated With Immunodeficiency–Centromeric Instability–Facial Dysmorphism Syndrome. Pediatrics, 2007, 120, e1341-e1344.	1.0	40
58	Early marrow transplantation in a pre-symptomatic neonate with late infantile metachromatic leukodystrophy does not halt disease progression. Bone Marrow Transplantation, 2007, 39, 309-310.	1.3	40
59	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget, 2017, 8, 90852-90867.	0.8	39
60	Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia, 2008, 22, 1256-1257.	3.3	37
61	lgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD. Bone Marrow Transplantation, 2012, 47, 360-368.	1.3	36
62	Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatric Nephrology, 2015, 30, 1367-1370.	0.9	36
63	Congenital Aplastic Anemia Caused by Mutations in the SBDS Gene: A Rare Presentation of Shwachman-Diamond Syndrome. Pediatrics, 2004, 114, e387-e391.	1.0	35
64	Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Therapeutic Drug Monitoring, 2014, 36, 465-472.	1.0	34
65	The Effect of Cidofovir on Adenovirus Plasma DNA Levels in Stem Cell Transplantation Recipients without T Cell Reconstitution. Biology of Blood and Marrow Transplantation, 2015, 21, 293-299.	2.0	34
66	High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric <scp>HSCT</scp> : a prospective multicentre study. British Journal of Haematology, 2017, 179, 772-780.	1.2	33
67	Effect of genetic variants <i>GSTA1</i> and <i>CYP39A1</i> and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics, 2013, 14, 1683-1690.	0.6	32
68	Determinants of the Relationship between Cytokine Production in Pregnant Women and Their Infants. PLoS ONE, 2009, 4, e7711.	1.1	31
69	RANKL Cytokine: From Pioneer of the Osteoimmunology Era to Cure for a Rare Disease. Clinical and Developmental Immunology, 2013, 2013, 1-9.	3.3	30
70	Sustained Engraftment of Cryopreserved Human Bone Marrow CD34 ⁺ Cells in Young Adult NSG Mice. BioResearch Open Access, 2014, 3, 110-116.	2.6	30
71	Introducing Newborn Screening for Severe Combined Immunodeficiency (SCID) in the Dutch Neonatal Screening Program. International Journal of Neonatal Screening, 2018, 4, 40.	1.2	30
72	Human Bocavirus in an Immunocompromised Child Presenting with Severe Diarrhea. Journal of Clinical Microbiology, 2009, 47, 1241-1243.	1.8	29

#	Article	IF	CITATIONS
73	Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anti-Cancer Drugs, 2006, 17, 1099-1105.	0.7	28
74	Child and parental adaptation to pediatric stem cell transplantation. Supportive Care in Cancer, 2009, 17, 707-714.	1.0	27
75	Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. Clinical Pharmacokinetics, 2019, 58, 1609-1620.	1.6	27
76	Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells. Journal of Allergy and Clinical Immunology, 2016, 137, 517-526.e3.	1.5	26
77	Parents' Perspectives and Societal Acceptance of Implementation of Newborn Screening for SCID in the Netherlands. Journal of Clinical Immunology, 2021, 41, 99-108.	2.0	25
78	Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematology,the, 2022, 9, e111-e120.	2.2	25
79	Sequential Switching of Dna Polymerase and Thymidine Kinase-Mediated Hsv-1 Drug Resistance in An Immunocompromised Child. Antiviral Therapy, 2004, 9, 97-104.	0.6	25
80	Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host Tâ€lymphocyte immunity. Transplant Infectious Disease, 2014, 16, 188-194.	0.7	20
81	Successful RAG1-SCID gene therapy depends on the level of RAG1 expression. Journal of Allergy and Clinical Immunology, 2014, 134, 242-243.	1.5	20
82	Macrophage activation syndrome after autologous stem cell transplantation for systemic juvenile idiopathic arthritis. European Journal of Pediatrics, 2002, 161, 685-686.	1.3	19
83	Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. Bone Marrow Transplantation, 2005, 35, 455-461.	1.3	19
84	Atypical varicella zoster infection associated with hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2009, 53, 226-228.	0.8	19
85	Reactivation of Human Herpes Virus-6 After Pediatric Stem Cell Transplantation. Pediatric Infectious Disease Journal, 2015, 34, 1118-1127.	1.1	19
86	Cost-effectiveness of newborn screening for severe combined immunodeficiency. European Journal of Pediatrics, 2019, 178, 721-729.	1.3	19
87	Parainfluenza virus 3 infection pre- and post-haematopoietic stem cell transplantation: re-infection or persistence?. Journal of Clinical Virology, 2004, 29, 320-322.	1.6	18
88	Dynamics of the Gut Microbiota in Children Receiving Selective or Total Gut Decontamination Treatment during Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1164-1171.	2.0	18
89	Limited Rescue of Osteoclast-Poor Osteopetrosis After Successful Engraftment by Cord Blood From an Unrelated Donor. Journal of Bone and Mineral Research, 2005, 20, 2264-2270.	3.1	16
90	Overview of 15-year severe combined immunodeficiency in the Netherlands: towards newborn blood spot screening. European Journal of Pediatrics, 2015, 174, 1183-1188.	1.3	16

#	Article	IF	CITATIONS
91	Deletion of the entire interferon- $\hat{1}^3$ receptor 1 gene causing complete deficiency in three related patients. Journal of Clinical Immunology, 2016, 36, 195-203.	2.0	16
92	Delayed immune recovery following sequential orthotopic liver transplantation and haploidentical stem cell transplantation in erythropoietic protoporphyria. Pediatric Transplantation, 2010, 14, 471-475.	0.5	15
93	Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study. Transplantation and Cellular Therapy, 2022, 28, 99.e1-99.e7.	0.6	15
94	Paediatric allogeneic bone marrow transplantation for homozygous \hat{l}^2 -thalassaemia, the Dutch experience. Bone Marrow Transplantation, 2003, 31, 1081-1087.	1.3	14
95	Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide. Bone Marrow Transplantation, 2021, 56, 2203-2211.	1.3	14
96	Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1043-1056.	1.3	13
97	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 196-202.	0.6	12
98	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 920-927.	2.0	11
99	Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients. Transplantation Direct, 2017, 3, e124.	0.8	10
100	Second Tier Testing to Reduce the Number of Non-actionable Secondary Findings and False-Positive Referrals in Newborn Screening for Severe Combined Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1762-1773.	2.0	10
101	HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia. Haematologica, 2009, 94, 302-304.	1.7	9
102	A novel mutation in CD132 causes X-CID withÂdefective T-cell activation and impaired humoral reactivity. Journal of Allergy and Clinical Immunology, 2011, 128, 1360-1363.e4.	1.5	9
103	Population Pharmacokinetic Modeling of Thymoglobulin in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival. Biology of Blood and Marrow Transplantation, 2014, 20, S96-S98.	2.0	9
104	Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?. Frontiers in Pharmacology, 2022, 13, 826004.	1.6	9
105	Bilateral Cavitary Pulmonary Consolidations in a Patient Undergoing Allogeneic Bone Marrow Transplantation for Acute Leukemiaa. Chest, 2003, 123, 929-934.	0.4	8
106	The use of intravenous pentamidine for the prophylaxis of Pneumocystis pneumonia in pediatric patients. Pediatric Blood and Cancer, 2017, 64, e26453.	0.8	8
107	Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1372-1374.	1.3	8
108	Future Perspectives of Newborn Screening for Inborn Errors of Immunity. International Journal of Neonatal Screening, 2021, 7, 74.	1.2	8

#	Article	IF	CITATIONS
109	Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency. Journal of Clinical Immunology, 2021, 41, 382-392.	2.0	7
110	Parainfluenza virus 4 detection in infants. European Journal of Pediatrics, 2005, 164, 528-529.	1.3	6
111	IL-7 and IL-15 Levels Reflect the Degree of T Cell Depletion during Lymphopenia and Are Associated with an Expansion of Effector Memory T Cells after Pediatric Hematopoietic Stem Cell Transplantation. Journal of Immunology, 2021, 206, 2828-2838.	0.4	6
112	Economic Evaluation of Different Screening Strategies for Severe Combined Immunodeficiency Based on Real-Life Data. International Journal of Neonatal Screening, 2021, 7, 60.	1.2	6
113	Abnormal Results of Newborn Screening for SCID After Azathioprine Exposure In Utero: Benefit of TPMT Genotyping in Both Mother and Child. Journal of Clinical Immunology, 2022, 42, 199-202.	2.0	6
114	Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 171-184.	2.0	5
115	Pulmonary hypertension in two severe combined immunodeficiency disease patients posthaematopoietic stem cell transplantation. British Journal of Haematology, 2004, 125, 405-406.	1.2	3
116	Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT. Bone Marrow Transplantation, 2021, 56, 2697-2704.	1.3	2
117	Benzylpenicillin Serum Concentrations in Neonates With Group B Streptococci Sepsis or Meningitis. Pediatric Infectious Disease Journal, 2021, 40, 434-439.	1.1	2
118	Lessons learned from the diagnostic work-up of a patient with the bare lymphocyte syndrome type II. Clinical Immunology, 2022, 235, 108932.	1.4	2
119	T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation. Journal of Clinical Immunology, 2022, 42, 1205-1222.	2.0	2
120	Low complement levels in paediatric systemic lupus erythematosus and the risk of bacteraemia. BMJ Case Reports, 2013, 2013, bcr2013010378-bcr2013010378.	0.2	1
121	Plasmapheresis to eliminate immunosuppressive alemtuzumab levels in a child with disseminated adenovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1671-1673.	1.3	1
122	Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool. Scientific Reports, 2021, 11, 19084.	1.6	1
123	The Effectiveness Of Cidofovir In Disseminated Adenovirus Infections After Pediatric HSCT Is Closely Related To Lymphocyte Reconstitution. Blood, 2013, 122, 3292-3292.	0.6	1
124	HLA-Identical Umbilical Cord Blood Transplantation from a Sibling Donor in Juvenile myelomonocytic Leukemia. Blood, 2008, 112, 4428-4428.	0.6	0
125	The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. Journal of Cell Biology, 2009, 185, i1-i1.	2.3	0
126	Immunological Prophile of FA. A Multicentric retrospective Analysis of 61 Patients. Blood, 2011, 118, 1347-1347.	0.6	0

#	Article	IF	CITATIONS
127	Wiskott-Aldrich syndrome protein–mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. Journal of Cell Biology, 2013, 200, i6-i6.	2.3	O
128	Imprint Of Early CMV Reactivation On The Reconstituting T-Lymphocyte Compartment One and Two Year After Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 3295-3295.	0.6	0
129	Treosulfan-Based Conditioning in Pediatric Hematopoietic Stem Cell Transplantation: A Prospective Study on Pharmacokinetics and Early Clinical Outcomes. Blood, 2014, 124, 3865-3865.	0.6	0